Brendon Ladd

951 total citations
19 papers, 584 citations indexed

About

Brendon Ladd is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Brendon Ladd has authored 19 papers receiving a total of 584 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in Brendon Ladd's work include PI3K/AKT/mTOR signaling in cancer (5 papers), Advanced Breast Cancer Therapies (4 papers) and DNA Repair Mechanisms (3 papers). Brendon Ladd is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (5 papers), Advanced Breast Cancer Therapies (4 papers) and DNA Repair Mechanisms (3 papers). Brendon Ladd collaborates with scholars based in United States, United Kingdom and China. Brendon Ladd's co-authors include Johnathan R. Whetstine, Capucine Van Rechem, Joshua C. Black, Jaegil Kim, Cristina Montagna, Gad Getz, Pascale Dufourcq, V Reinke, Julián Cerón and Yang Shi and has published in prestigious journals such as Cell, Genes & Development and Molecular Cell.

In The Last Decade

Brendon Ladd

18 papers receiving 576 citations

Peers

Countries citing papers authored by Brendon Ladd

Since Specialization

Citations

This map shows the geographic impact of Brendon Ladd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brendon Ladd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brendon Ladd more than expected).

Fields of papers citing papers by Brendon Ladd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brendon Ladd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brendon Ladd. The network helps show where Brendon Ladd may publish in the future.

Co-authorship network of co-authors of Brendon Ladd

This figure shows the co-authorship network connecting the top 25 collaborators of Brendon Ladd. A scholar is included among the top collaborators of Brendon Ladd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brendon Ladd. Brendon Ladd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer 2025 ·Journal of Medicinal Chemistry ·Benjamin C. Milgram, (unknown), Natasja Brooijmans, Jack A. Henderson, Brendan J. Hilbert, Michael R. Huff, Takahiro Ito, Erica L. Jackson, (unknown), Brendon Ladd, (unknown), Raymond Pagliarini, Simon Roberts, Sébastien Ronseaux, Darrin D. Stuart, Weixue Wang, (unknown)	0
2	STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts 2023 ·Cancer Discovery ·(unknown), David J. St. Jean, (unknown), Brendon Ladd, Brendan J. Hilbert, Weixue Wang, (unknown), (unknown), Gregory V. Kryukov, Natasja Brooijmans, (unknown), Philip Jonsson, (unknown), (unknown), Erica L. Jackson, Marcus D. Goncalves, Darrin D. Stuart	41
3	Abstract P4-07-04: STX-478, a mutant-selective PI3Kα H1047X inhibitor clinical candidate with a best-in-class profile: Pharmacology and therapeutic activity as monotherapy and in combination in breast cancer xenograft models 2023 ·Cancer Research ·(unknown), David J. St. Jean, Brendon Ladd, (unknown), (unknown), (unknown), (unknown), Weixue Wang, (unknown), Darrin D. Stuart, (unknown)	3
4	Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile 2022 ·European Journal of Cancer ·(unknown), Benjamin C. Milgram, (unknown), (unknown), (unknown), Takahiro Ito, (unknown), Brendon Ladd, (unknown), (unknown), (unknown), (unknown), Aaron N. Hata, (unknown), Darrin D. Stuart	2
5	Abstract LB194: Discovery and characterization of a mutant selective PI3KαH1047Xinhibitor with a best-in-class profile 2022 ·Cancer Research ·(unknown), David J. St. Jean, (unknown), Weixue Wang, Gregory V. Kryukov, (unknown), (unknown), (unknown), Brendon Ladd, (unknown), Darrin D. Stuart	3
6	A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination 2021 ·SLAS DISCOVERY ·(unknown), Roman V. Agafonov, Lydia M. Emerson, Marta Isasa, Richard W. Deibler, Jeffrey R. Simard, (unknown), Brendon Ladd, Linda Lee, (unknown), Stephen L. Archer, Mark E. Fitzgerald, (unknown), Christopher G. Nasveschuk, (unknown), Günther Kern, David A. Proia, Andrew J. Phillips, Stewart L. Fisher	9
7	Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations 2016 ·Oncotarget ·Brendon Ladd, Anne Marie Mazzola, Teeru Bihani, Zhongwu Lai, James Bradford, Michael P. Collins, Evan Barry, Anne U. Goeppert, Hazel M. Weir, (unknown), (unknown), Morvarid Mohseni, Elaine M. Hurt, (unknown), Haifeng Bao, Robert E. Hollingsworth, Corinne Reimer, Michael Zinda, Stephen E. Fawell, Celina M. D’Cruz	22
8	Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation 2016 ·Oncotarget ·Ryan E. Henry, Evan Barry, Lillian Castriotta, Brendon Ladd, Aleksandra Markovets, Garry Beran, Yongxin Ren, Feng Zhou, Ammar Adam, Michael Zinda, Corinne Reimer, Weiguo Qing, Weiguo Su, Edwin Clark, Celina M. D’Cruz, Alwin G. Schuller	27
9	Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors 2015 ·Molecular Cancer Therapeutics ·Barry R. Davies, (unknown), Armelle Logié, Claire Crafter, Lyndsey Hanson, Vivien N. Jacobs, Neil H. James, Philippa Dudley, Kelly Jacques, Brendon Ladd, Celina M. D’Cruz, Michael Zinda, Justin P.O. Lindemann, Makoto Kodaira, Kenji Tamura, Emma Jenkins	54
10	A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors 2015 ·Cancer Discovery ·Capucine Van Rechem, Joshua C. Black, Patricia Greninger, (unknown), Carlos Donado, (unknown), Brendon Ladd, David C. Christiani, Cyril H. Benes, Johnathan R. Whetstine	22
11	Hypoxia drives transient site-specific copy gain and drug-resistant gene expression 2015 ·Genes & Development ·Joshua C. Black, (unknown), Jaegil Kim, Kelly M. Biette, Capucine Van Rechem, Brendon Ladd, (unknown), Carlos Donado, Hamid Mattoo, Benjamin P. Kleinstiver, Bing Song, Ana Andriani, J. Keith Joung, Othon Iliopoulos, Cristina Montagna, Shiv Pillai, Gad Getz, Johnathan R. Whetstine	66
12	Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers 2014 ·Oncotarget ·Teeru Bihani, Scott A. Ezell, Brendon Ladd, Shaun Grosskurth, Anne Marie Mazzola, (unknown), Corinne Reimer, Michael Zinda, Stephen E. Fawell, Celina M. D’Cruz	53
13	KDM4A Lysine Demethylase Induces Site-Specific Copy Gain and Rereplication of Regions Amplified in Tumors 2013 ·Cell ·Joshua C. Black, Amity L. Manning, Capucine Van Rechem, Jaegil Kim, Brendon Ladd, Juok Cho, Cristiana M. Pineda, Nancy E. Murphy, Danette L. Daniels, Cristina Montagna, Peter W. Lewis, Kimberly Glass, (unknown), Nicholas J. Dyson, Gad Getz, Johnathan R. Whetstine	171
14	Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity 2013 ·DNA repair ·Brendon Ladd, Jeffrey J. Ackroyd, J. Kevin Hicks, Christine E. Canman, (unknown), Donna S. Shewach	13
15	Unrepairable DNA double-strand breaks initiate cytotoxicity with HSV-TK/ganciclovir 2011 ·Cancer Gene Therapy ·Brendon Ladd, Jessica J. O’Konek, Leo J. Ostruszka, Donna S. Shewach	17
16	Abstract 5374: Synergistic tumor cell killing with ganciclovir and vorinostat is due to inhibition of homologous recombination 2011 ·Cancer Research ·Brendon Ladd, Donna S. Shewach	8
17	Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity 2009 ·Mutation research. Fundamental and molecular mechanisms of mutagenesis ·Jessica J. O’Konek, Brendon Ladd, (unknown), (unknown), Paul D. Boucher, (unknown), John A. Secrist, Donna S. Shewach	2
18	Computational Causal Reasoning Models of Mechanisms of Androgen Stimulation in Prostate Cancer 2006 ·PubMed ·Dexter Pratt, (unknown), Matthews, Phillip G. Febbo, Raanan Berger, (unknown), Joseph Levy, (unknown), Jin Sun, Brendon Ladd, Keith Elliston	2
19	Regulation of Tissue-Specific and Extracellular Matrix-Related Genes by a Class I Histone Deacetylase 2005 ·Molecular Cell ·Johnathan R. Whetstine, Julián Cerón, Brendon Ladd, Pascale Dufourcq, V Reinke, Yang Shi	69

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact